Coverage
Healthcare investment & market access
Payers, formulary committee members, and health economists who can tell you what will actually get reimbursed, and why.
Expert types
Common use cases
Payer sentiment reads
Get a directional view on formulary placement and prior-authorization likelihood ahead of a launch or readout.
Health economic model validation
Pressure-test cost-effectiveness assumptions with the health economists who actually build these models.
Market access strategy
Understand the realistic reimbursement pathway for a novel mechanism or device category.
Investment diligence
Ground a therapeutic-area or diagnostics thesis in real payer and provider adoption dynamics.
Questions we help answer
- “Would a mid-size regional payer actually place this on formulary at launch, or wait for real-world data?”
- “What prior-authorization criteria is a payer medical director realistically going to set for this drug class?”
- “Does this health-economic model's assumed adherence rate hold up against what plan actuaries actually see?”
- “How much price pressure will this indication face once a biosimilar enters the class?”
In practice
A biotech's market access team needed a payer read on a novel mechanism ahead of a Phase 3 readout, without tipping their hand to the wrong audience. We ran a small, tightly-scoped panel of formulary committee members and health economists under guardrails set by the client's own medical affairs team, and delivered a directional payer view months before launch planning would normally allow it.
Composite example, illustrative only.
How we deliver this
Who this serves